The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines

Front Endocrinol (Lausanne). 2020 Oct 2:11:569250. doi: 10.3389/fendo.2020.569250. eCollection 2020.

Abstract

Metabolic dysfunction is intertwined with the pathophysiology of both diabetes and cardiovascular disease. Recently, one particular lipid class has been shown to influence the development and sustainment of these diseases: ceramides. As a subtype of sphingolipids, these species are particularly central to many sphingolipid pathways. Increased levels of ceramides are known to correlate with impaired cardiovascular and metabolic health. Furthermore, the interaction between ceramides and adipokines, most notably adiponectin and leptin, appears to play a role in the pathophysiology of these conditions. Adiponectin appears to counteract the detrimental effects of elevated ceramides, largely through activation of the ceramidase activity of its receptors. Elevated ceramides appear to worsen leptin resistance, which is an important phenomenon in the pathophysiology of obesity and metabolic syndrome.

Keywords: adipokine; adiponectin; adiponectin receptors; ceramidase; leptin; sphingolipids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adipokines / metabolism*
  • Animals
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / metabolism*
  • Ceramides / adverse effects
  • Ceramides / metabolism*
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / metabolism*
  • Humans
  • Insulin Resistance / physiology*
  • Metabolic Syndrome / diagnosis
  • Metabolic Syndrome / metabolism
  • Obesity / metabolism
  • Obesity / pathology

Substances

  • Adipokines
  • Ceramides